Home＞BUSINESS
Sanofi, Asahi Kasei Pharma Tie Up for Anti RA Treatment Kevzara(Dec.11.2017)
Sanofi and Asahi Kasei Pharma said on December 8 that they have entered into a license agreement for the marketing of Sanofi’s rheumatoid arthritis (RA) treatment Kevzara subcutaneous injection (sarilumab) in Japan ...
(LOG IN FOR FULL STORY)
-
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand Oct.19
- Takeda Earns Japan Clearance for Shire Acquisition Oct.19
- Asahi Kasei Obtains Patent License for iPS Cell-Derived Cartilage Regeneration Technology Oct.18
- Sumitomo Dainippon to Invest in, Conduct Joint R&D with Cyborg Tech Startup Oct.18
- Nippon Shinyaku Seeks Japan Approval for Hepatic VOD Treatment Defibrotide Oct.18
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand(Oct.19)
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications(Oct.19)
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan(Oct.19)
- Takeda Earns Japan Clearance for Shire Acquisition(Oct.19)
- Council OKs Public Knowledge-Based Applications for Add’l Pediatric Indications for Blopress(Oct.19)
